Shares of Day One Biopharmaceuticals Inc. (NASDAQ: DAWN) tumbled 11.34% in after-hours trading on Tuesday, despite the company reporting better-than-expected earnings per share for the second quarter of 2025. The sharp decline highlights investors' concerns over missed revenue targets and ongoing net losses.
Day One reported a quarterly loss of $(0.29) per share, surpassing analyst expectations of $(0.35) by 17.14%. However, this still represents a significant increase in losses compared to the same period last year when the company reported a loss of $(0.05) per share. More importantly, the biopharmaceutical firm's quarterly sales of $33.908 million fell short of the analyst consensus estimate of $35.926 million by 5.62%, despite showing a substantial year-over-year increase of 313.92%.
The company's net income for the quarter remained negative at $30.322 million, raising concerns about its path to profitability. While Day One provided guidance for its flagship product Ojemda, projecting full-year 2025 net product revenue between $140 to $150 million, it seems the market was looking for stronger overall performance and a clearer route to positive earnings. The after-hours plunge suggests that investors are reassessing the company's growth trajectory and financial health in light of these mixed results.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.